Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia

Journal of Molecular Diagnostics

Volumn 11, Issue 3, 2009, Pages 201-210

  Morley, Alexander A ^a,e   Latham, Sue ^a   Brisco, Michael J ^a   Sykes, Pamela J ^a   Sutton, Rosemary ^b   Hughes, Elizabeth ^a   Wilczek, Vicki ^a   Budgen, Bradley ^a   Van Zanten, Katrina ^a   Kuss, Bryone J ^a   Venn, Nicola C ^b   Norris, Murray D ^b   Crock, Catherine ^c   Storey, Colin ^d   Revesz, Tamas ^d   Waters, Keith ^c  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; IMMUNOGLOBULIN HEAVY CHAIN; OLIGONUCLEOTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; DNA DETERMINATION; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; IMMUNOGLOBULIN GENE; INTERMETHOD COMPARISON; MINIMAL RESIDUAL DISEASE; PRE B LYMPHOCYTE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; FLUORESCENCE; PATHOLOGY; POLYMERASE CHAIN REACTION;

CHILD; DNA, NEOPLASM; FLUORESCENCE; HUMANS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SENSITIVITY AND SPECIFICITY;

EID: 67149138470     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.080048     Document Type: Article

References (23)

1. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994, 343:196-200
2. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998, 339:591-598
3. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui CH, Campana D: Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998, 351:550-554
4. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352: 1731-1738
5. Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA: Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. J Mol Diagn 2009, 11:194-200
6. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ: European Study Group on MRDdiALL: Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007, 21:604-611
7. Deagle BE, Eveson JP, Jarman SN: Quantification of damage in DNA recovered from highly degraded samples: a case study of DNA in faeces. Frontiers Zool 2006, 3:11
8. van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034
9. Sutton R, Bahar AY, Kwan E, Giles JE, Venn NC, Tran S, Hackenberg H, Marshall GM, Haber M, van der Velden V, Norris MD: Improving minimal residual disease testing in precursor-B-ALL based on immunoglobulin kappa and heavy chain gene rearrangements. Leukemia 2008, 22:2265-2267
10. van der Velden VH, Panzer-Grumayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ: Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007, 21:706-713
11. Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G: Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992, 10:1879-1888
12. Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D, Gribben JG: Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 2000, 95:2651-2658
13. Nakao M, Janssen JW, Flohr T, Bartram CR: Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res 2000, 60:3281-3289
14. van der Velden VH. Wijkhuijs JM. van Dongen JJ. Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring. Leukemia 2008, 22:641-644
15. van der Velden VH, Hoogeveen PG, Pieters R, van Dongen JJ: Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia. Br J Haematol 2006, 133:382-388
16. Morley AA, Latham S, Brisco MJ, Sykes PJ, Kuss BJ, Waters K: Improved measurement of minimal residual disease (MRD). Blood (ASH Annual Meeting Abstracts) 2006, 108:2284
17. Brisco MJ, Sykes PJ, Hughes E, Dolman G, Neoh SH, Peng LM, Toogood I, Morley AA: Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol 1997, 99:314-319
18. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002, 100: 2399-2402
19. Li A, Zhou J, Zuckerman D, Rue M, Dalton V, Lyons C, Silverman LB, Sallan SE, Gribben JG: Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood 2003, 102:4520-4526
20. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ: Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002, 99: 2315-2323
21. de Haas V, Verhagen OJ, von dem Borne AE, Kroes W, van den Berg H, van der Schoot CE: Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy. Leukemia 2001, 15:134-140
22. Choi S, Henderson MJ, Kwan E, Beesley AH, Sutton R, Bahar AY, Giles J, Venn NC, Pozza LD, Baker DL, Marshall GM, Kees UR, Haber M, Norris MD: Relapse in children with acute lymphoblastic leukemia involving selection of a pre-existing drug-resistant subclone. Blood 2007, 110:632-639
23. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR: International BFM Study Group (I-BFM-SG) (2008) Minimal residual disease (MRD)-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia (ALL). Leukemia 2008, 22:771-782